NCT04145492

Brief Summary

The aim of this study is to assess the effect of supplementation of vitamin K2 (menaquinone, MK-7) and cholecalciferol (inactive vitamin D) on circulating levels of calcification regulators and to assess their safety in pediatric patients on regular hemodialysis patients.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Sep 2019

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2019

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

October 28, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 30, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2020

Completed
Last Updated

October 30, 2019

Status Verified

October 1, 2019

Enrollment Period

4 months

First QC Date

October 28, 2019

Last Update Submit

October 29, 2019

Conditions

Keywords

Hemodialysis and Vitamin K2

Outcome Measures

Primary Outcomes (2)

  • Uncarboxylated MGP

    Measuring serum level of Uncarboxylated MGP as a marker for calcification

    4 months

  • Uncarboxylated osteocalcin

    Measuring serum level of Uncarboxylated osteocalcin as a marker for calcification

    4 months

Study Arms (4)

Vitamin K2 group

ACTIVE COMPARATOR

15 patients will take 90 ug of vitamin K2 (MK-7) daily in addition to the standard therapy for 4 months.

Drug: Vitamin K2

Cholecalciferol group

ACTIVE COMPARATOR

15 patients will take 10 ug of vitamin inactive vitamin D daily in addition to the standard therapy for 4 months.

Drug: Cholecalciferol (inactive vitamin D)

Vitamin K2 and Cholecalciferol group

ACTIVE COMPARATOR

15 patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D to daily in addition to the standard therapy for 4 months.

Drug: Cholecalciferol (inactive vitamin D)Drug: Vitamin K2 and Cholecalciferol

Control group

NO INTERVENTION

15 patients will take the standard therapy.

Interventions

Patients will take 90 ug of vitamin K2

Also known as: Group 1
Vitamin K2 group

Patients will take 10 ug of vitamin inactive vitamin D

Also known as: Group 2
Cholecalciferol groupVitamin K2 and Cholecalciferol group

Patients will take 90 ug of vitamin K2 (MK-7) in addition 10 ug of vitamin inactive vitamin D

Also known as: Group 3
Vitamin K2 and Cholecalciferol group

Eligibility Criteria

Age6 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Patients aged 6-18 years
  • Patients on hemodialysis since 3 months or longer
  • Hemodialysis frequency 3 times or more weekly

You may not qualify if:

  • Patients with life expectancy \< 3 months
  • Patients taking warfarin
  • Patients with known intestinal malabsorption

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Radwa Maher El Borolossy

Cairo, 0000, Egypt

RECRUITING

Related Publications (1)

  • El Borolossy R, El-Farsy MS. The impact of vitamin K2 and native vitamin D supplementation on vascular calcification in pediatric patients on regular hemodialysis. A randomized controlled trial. Eur J Clin Nutr. 2022 Jun;76(6):848-854. doi: 10.1038/s41430-021-01050-w. Epub 2021 Nov 29.

MeSH Terms

Conditions

Kidney Failure, Chronic

Interventions

Vitamin K 2CholecalciferolCalcifediol

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Vitamin KNaphthoquinonesNaphthalenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsPhytolDiterpenesTerpenesQuinonesPolycyclic CompoundsCholestenesCholestanesSteroidsFused-Ring CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipidsHydroxycholecalciferols

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
lecturer of clinical pharmacy

Study Record Dates

First Submitted

October 28, 2019

First Posted

October 30, 2019

Study Start

September 1, 2019

Primary Completion

January 1, 2020

Study Completion

February 1, 2020

Last Updated

October 30, 2019

Record last verified: 2019-10

Locations